LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Închisă

3.33 -7.5

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.3

Maxim

3.4

Indicatori cheie
By Trading Economics
Venit	-511K -28M
Vânzări	-13M 2.6M
EPS	-0.47
Marjă de profit	-1,077.401
Angajați	141
EBITDA	-455K -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+354.65% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-5.4M 229M
Deschiderea anterioară	10.83
Închiderea anterioară	3.33

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iun. 2026, 19:20 UTC

Principalele dinamici ale pieței

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 iun. 2026, 21:27 UTC

Câștiguri

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 20:20 UTC

Achiziții, Fuziuni, Preluări

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 iun. 2026, 20:19 UTC

Achiziții, Fuziuni, Preluări

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 iun. 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 iun. 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 iun. 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 iun. 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 iun. 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 iun. 2026, 18:33 UTC

Achiziții, Fuziuni, Preluări

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 iun. 2026, 17:50 UTC

Câștiguri

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 iun. 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 iun. 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 iun. 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 iun. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 iun. 2026, 15:44 UTC

Achiziții, Fuziuni, Preluări

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 iun. 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 iun. 2026, 15:25 UTC

Câștiguri

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 iun. 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 iun. 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 iun. 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 iun. 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 iun. 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

354.65% sus

Prognoză pe 12 luni

Medie 15.14 USD 354.65%

Maxim 25 USD

Minim 8 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.